Conduct prospective trials to explore the long-term impacts of SGLT2 inhibitor therapy on arrhythmic outcomes in different ejection fraction subgroups.Investigate the direct effects of SGLT2 inhibitors on cardiac electrophysiology and arrhythmogenesis.Explore biomarkers associated with SGLT2 inhibitor therapy response in reducing SCD risk among HF patients. The gene discussed is SLC5A2; the disease is hydrops fetalis.